Endpoints News 生物医药· Kyle LaHucik·· 2026-10-09AI 评分38
TRexBio 定价 1.17 亿美元 IPO 拟推 Treg 疗法;Retension 高血压候选药以 4500 万美元 Nasdaq 首日上市
TRexBio prices $117M IPO for Tregs as Retension lands $45M Nasdaq debut for hypertension
AI 导读
TRexBio 定价 1.17 亿美元 IPO,拟募集资金用于 Treg 疗法研发。与此同时,专注高血压治疗的 Retension 以 4500 万美元估值在纳斯达克首发上市。两家企业均借 Eli Lilly 合作及诺贝尔奖背景吸引资本。
正文
The appetite for biotech IPOs remains strong, especially when Eli Lilly and Nobel Prize-winning science are involved.
TRexBio
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
来源:Endpoints News 生物医药 · endpoints.news